Appili Therapeutics

Appili Therapeutics company information, Employees & Contact Information

Updated June 2026

Quick answer

Appili Therapeutics is a Biotechnology Research company and founded in 2015. It has approximately 20 employees on record. Contact data was last refreshed in June 2026. Find Appili Therapeutics's verified employee emails, phone numbers, headquarters address, and key decision makers below.

Appili Therapeutics is an infectious disease biopharmaceutical company that is purposefully built, portfolio-driven, and people-focused to fulfill its mission of solving life-threatening infections. By systematically identifying urgent infections with unmet needs, Appili’s goal is to strategically develop a pipeline of novel therapies to prevent deaths and improve lives.

Company Details

Employees
20
Founded
2015
Address
Halifax, Nova Scotia B3h 0a8, Ca
Phone
(902)442-4655
Email
in****@****ics.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Halifax, Nova Scotia
Looking for a particular Appili Therapeutics employee's phone or email?

Appili Therapeutics Questions

News

Appili Therapeutics (TSX: APLI) to attend BARDA event; $40M NIAID award, $66M funding - Stock Titan

Appili Therapeutics (TSX: APLI) to attend BARDA event; $40M NIAID award, $66M funding Stock Titan

Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc. - Yahoo Finance

Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc. Yahoo Finance

Appili Therapeutics to Attend BARDA Innovation Symposium 2025 - Lelezard

Appili Therapeutics to Attend BARDA Innovation Symposium 2025 Lelezard

Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc. - Yahoo Finance

Appili Therapeutics Announces Formal Termination of Arrangement Agreement with Aditxt Inc. Yahoo Finance

First-Ever Human Fungal Vaccine: Appili, Vitalex Win $40M to Combat Deadly Candida Infections Killing 3.8M Annually - Stock Titan

First-Ever Human Fungal Vaccine: Appili, Vitalex Win $40M to Combat Deadly Candida Infections Killing 3.8M Annually Stock Titan

Aditxt agrees to acquire Appili Therapeutics - Pharmaceutical Technology

Aditxt agrees to acquire Appili Therapeutics Pharmaceutical Technology

Appili Therapeutics – Press Release Correction - FinancialContent

Appili Therapeutics – Press Release Correction FinancialContent

Considerations for prevention of and emergency response to tularemia outbreaks in Ukraine: vaccine involvement - Frontiers

Considerations for prevention of and emergency response to tularemia outbreaks in Ukraine: vaccine involvement Frontiers

Appili Therapeutics Secures Shareholder Approval for Strategic Initiatives - TipRanks

Appili Therapeutics Secures Shareholder Approval for Strategic Initiatives TipRanks

Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01 - The Manila Times

Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01 The Manila Times

Reformulated Metronidazole Granted Orphan Drug for CDI in Children - Medical Professionals Reference

Reformulated Metronidazole Granted Orphan Drug for CDI in Children Medical Professionals Reference

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024 - FinancialContent

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2024 FinancialContent

Appili Therapeutics Secures $40 Million Contract for Fungal Vaccine Development - TipRanks

Appili Therapeutics Secures $40 Million Contract for Fungal Vaccine Development TipRanks

Aditxt Secures Overwhelming Shareholder Approval for Appili Therapeutics Acquisition - Stock Titan

Aditxt Secures Overwhelming Shareholder Approval for Appili Therapeutics Acquisition Stock Titan

Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update - FinancialContent

Appili Therapeutics Announces Results of Annual Meeting of Shareholders and Provides Corporate Update FinancialContent

Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference - The Manila Times

Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference The Manila Times

Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference - FinancialContent

Appili Therapeutics to Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference FinancialContent

Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan - FinancialContent

Appili Therapeutics Announces Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Provides Update on Bridge Loan FinancialContent

Appili Therapeutics Presents at the 10th International Tularemia Conference - FinancialContent

Appili Therapeutics Presents at the 10th International Tularemia Conference FinancialContent

Top Appili Therapeutics Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant